Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for Rhythm Pharmaceuticals (RYTM) over the last 7 years, with Q4 2024 value amounting to $1.3 million.

  • Rhythm Pharmaceuticals' Current Deferred Revenue changed 0.0% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.3 million for FY2024, which is 0.0% changed from last year.
  • Rhythm Pharmaceuticals' Current Deferred Revenue amounted to $1.3 million in Q4 2024, which was down 0.0% from $1.3 million recorded in Q3 2024.
  • In the past 5 years, Rhythm Pharmaceuticals' Current Deferred Revenue registered a high of $9.4 million during Q1 2022, and its lowest value of $1.3 million during Q2 2023.
  • Moreover, its 4-year median value for Current Deferred Revenue was $1.3 million (2023), whereas its average is $2.5 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Current Deferred Revenue crashed by 8487.29% in 2023, and later changed by 0.0% in 2024.
  • Quarter analysis of 4 years shows Rhythm Pharmaceuticals' Current Deferred Revenue stood at $7.0 million in 2021, then crashed by 79.51% to $1.4 million in 2022, then decreased by 10.32% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q4 2024, $1.3 million for Q3 2024, and $1.3 million during Q2 2024.